StockDuty ← Dashboard Nov 05, 2026 11:12 AM ET
SignalCorporate

Schrödinger outlines 2026 ACV of $222M-$232M while raising drug discovery revenue to $75M-$85M

Schrödinger targets 2026 ACV of $222M-$232M and drug discovery revenue of $75M-$85M.

What happened: Schrödinger outlined 2026 ACV of $222M-$232M and raised its drug discovery revenue target to $75M-$85M during its Q3 2026 earnings call. Key numbers: 2026 ACV guidance $222M-$232M; drug discovery revenue raised to $75M-$85M; ACV grew 17%, or 24% excluding contribution. Why it matters: Management said Q3 results reflect sustained commercial momentum and strong progress toward the long-range goals outlined earlier this year.
Schrödinger outlined 2026 ACV of $222M-$232M and raised its drug discovery revenue target to $75M-$85M during its Q3 2026 earnings call.
Management said Q3 results reflect sustained commercial momentum and strong progress toward the long-range goals outlined earlier this year.
Sources